PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety

医学 乳腺癌 内科学 荟萃分析 肿瘤科 新辅助治疗 PARP抑制剂 癌症 聚ADP核糖聚合酶 生物化学 化学 聚合酶 基因
作者
Xiaomeng Jia,Kainan Wang,Qiping Zhuo,Zuowei Zhao,Man Li
出处
期刊:Clinical Breast Cancer [Elsevier BV]
卷期号:24 (5): 392-398.e3 被引量:4
标识
DOI:10.1016/j.clbc.2024.02.020
摘要

Poly-ADP ribose polymerase inhibitor (PARPi) is approved for HER2-negative advanced breast cancer with BRCA1/2 mutation. In recent years, many studies have explored the application of PARPi in neoadjuvant therapy, but failed to reach a unified conclusion. PubMed, Clinicaltrials.gov, Cochrane CENTRAL, Embase, and key oncological meetings for trials were searched for studies reporting neoadjuvant regimens with PARPi in HER2-negative breast cancer. Pathological complete response (pCR), residual cancer burden (RCB), breast-conservation surgery rate (BCSR), clinical response, and adverse events were extracted and pooled in a meta-analysis using the Mantel Haenszel random/fixed effects model. Subgroup analyses of pCR were conducted according to BRCA1/2 status, and hormone receptor (HR) status. Five studies (N = 1223) were included, the addition of PARPi to neoadjuvant regimens significantly increased pCR rates (HR 1.45, 95%CI 1.09-1.92, P = .01, I2 = 86%). In subgroup analysis, the addition of PARPi increased the pCR rate both in HR-positive (n = 383) and HR-negative (n = 431) subgroups, which showed a dominant effect of PARPi regardless of HR status (HR 2.07, 95%CI 1.33-3.23, P = .001, I2 = 0%; HR 1.85, 95%CI 1.39-2.26, P < .0001, I2 = 0%, respectively). However, when we performed a subgroup analysis based on the status of BRCA1/2, no further benefit for PARPi was found. Adverse reactions were generally tolerable. Other outcome indexes, including RCB, clinical response, BCSR, and PARPi did not show a clinical benefit. Regardless of BRCA1/2 status, PARPi in neoadjuvant therapy, can improve the pCR rate of HER2-negative breast cancer, especially in HR-positive patients. Thus, we should have performed larger randomized trials and provided a stronger evidence-based basis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被tongluobing采纳,获得30
1秒前
852的应助被来日方长采纳,获得10
2秒前
Akim的应助被yang采纳,获得10
2秒前
CipherSage的应助被成功上岸采纳,获得10
2秒前
3秒前
3秒前
刘轩完成签到,获得积分10
3秒前
3秒前
连钧发布了新的文献求助10
4秒前
啊汪~发布了新的文献求助10
4秒前
5秒前
5秒前
学霸业的应助被一丁雨采纳,获得10
6秒前
7秒前
8秒前
8秒前
rylinn完成签到,获得积分10
9秒前
我行发布了新的文献求助10
10秒前
科研通AI6.3的应助被yk采纳,获得10
10秒前
小雨发布了新的文献求助10
11秒前
zhou发布了新的文献求助10
12秒前
拔丝香芋发布了新的文献求助10
12秒前
13秒前
13秒前
14秒前
14秒前
豆包不当干粮完成签到,获得积分10
14秒前
成功上岸发布了新的文献求助10
16秒前
yang发布了新的文献求助10
17秒前
拼搏太英完成签到,获得积分10
17秒前
张维为发布了新的文献求助10
18秒前
fantasy的应助被科研通管家采纳,获得10
19秒前
CAOHOU的应助被科研通管家采纳,获得10
19秒前
19秒前
传奇3的应助被科研通管家采纳,获得10
19秒前
斯文败类的应助被科研通管家采纳,获得10
19秒前
贤于发布了新的文献求助10
19秒前
Lny的应助被科研通管家采纳,获得10
19秒前
fantasy的应助被科研通管家采纳,获得10
19秒前
DW的应助被科研通管家采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191044
求助须知:如何正确求助?哪些是违规求助? 9578050
关于积分的说明 21856381
捐赠科研通 7790198
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560326
邀请新用户注册赠送积分活动 2483221